Passage Bio, Inc.
NASDAQ · us_market
No AI insight generated yet for this ticker.
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other programs for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is based in Philadelphia, Pennsylvania.
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| RenTech | quant | 133.6K | $1.05M | 0.00% | Added+22.5% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-03-03 | -2.80 | -4.09 | -46.28% |
| 2025-11-10 | -2.97 | -2.44 | +17.91% |
| 2025-08-12 | -4.15 | -2.96 | +28.67% |
| 2025-05-13 | -4.47 | -5.00 | -11.94% |
| 2025-03-04 | -4.00 | -4.00 | — |
| 2024-11-13 | -4.67 | -4.71 | -0.93% |
| 2024-08-08 | -6.20 | -5.20 | +16.13% |
| 2024-05-14 | -6.90 | -6.00 | +13.04% |
| 2024-03-04 | -8.00 | -6.00 | +25.00% |
| 2023-11-13 | -8.80 | -7.93 | +9.91% |
| 2023-08-07 | -9.55 | -8.80 | +7.85% |
| 2023-05-11 | -10.15 | -12.60 | -24.14% |
| 2023-03-06 | -9.80 | -9.80 | — |
| 2022-11-10 | -15.44 | -9.80 | +36.53% |
| 2022-08-04 | -15.93 | -14.60 | +8.37% |
| 2022-05-16 | -18.38 | -15.80 | +14.04% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| PASG | +16.10% | -27.88% | -51.10% | -33.83% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | +13.13% | -23.24% | -47.66% | -46.52% |